Colon cleansing compositions

Details Colon cleansing compositions Colon cleansing compositions

2006-12-08

2010-02-09

Weddington, Kevin (Department: 1614)

Drug, bio-affecting and body treating compositions

Digestive system regulator containing solid synthetic...

C514S474000, C514S892000

Reexamination Certificate

active

07658914

ABSTRACT:
A composition comprising, per liter of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavorings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.

REFERENCES:
patent: 3211614 (1965-10-01), Embring et al.
patent: 5077048 (1991-12-01), Kimura et al.
patent: 5274001 (1993-12-01), Borody
patent: 5458890 (1995-10-01), Williford et al.
patent: 5496535 (1996-03-01), Kirkland
patent: 5858024 (1999-01-01), De Lacharriere et al.
patent: 6048901 (2000-04-01), Cleveland et al.
patent: 6946149 (2005-09-01), Cleveland
patent: 7169381 (2007-01-01), Barras et al.
patent: 2005/0129781 (2005-06-01), Skiendzielewski et al.
patent: 2006/0029570 (2006-02-01), Aronson et al.
patent: 0 436 061 (1993-05-01), None
patent: 0 397 689 (1994-05-01), None
patent: 11-130674 (1999-05-01), None
patent: 11-228423 (1999-08-01), None
patent: 2111741 (1998-05-01), None
patent: WO 87/00754 (1987-02-01), None
patent: WO 89/05659 (1989-06-01), None
patent: WO 98/43654 (1998-10-01), None
patent: WO 03/037298 (2003-05-01), None
patent: WO 03/092589 (2003-11-01), None
patent: WO 2005/049049 (2005-06-01), None
patent: WO 2005/051361 (2005-06-01), None
patent: WO 2005/120501 (2005-12-01), None
Baba et al.,Therapeutic Research, 14(2): 189 (1993).
Minegishi et al.,New Drugs and Clinical Pathology, 44(3): 265-269 (1995).
U.S. Patent Office Action dated Oct. 5, 2009, in U.S. Appl. No. 11/635,862, (filed Dec. 8, 2006), which is a co-pending application of Applicants based on the same parent (now US 7,169,381).
Toledo et al., “Review article: colon cleansing preparation for gastrointestinal procedures.”Ailment. Pharmacol. Ther., 15: 605-611 (2001).
U.S. Patent Office Action dated Oct. 5, 2009, in U.S. Appl. No. 11/640,085, (filed Dec. 15, 2006), which is a co-pending application of Applicants based on the same parent (now US 7,169,381).
Merriam-Webster Dictionary [Online]. “Osmolarity”. [Retrieved Sep. 30, 2009]. Retrieved from the Internet: <URL: http://www.m-w.com/dictionary/osmolarity>.
Merriam-Webster Dictionary [Online]. “Osmolality”. [Retrieved Sep. 30, 2009]. Retrieved from the Internet: <URL: http://www.m-w.com/dictionary/osmolality>.
“Sodium Ascorbate”, Monograph 8525, The Merck Index (Eleventh Edition), Merck & Co., Inc., p. 1357 (1989).
Notice of Opposition to a European Patent (EP 1567193), Opponent: Teva Pharmaceutical Industries Ltd.; including documents relied on in the Notice of Opposition, including WO 89/05659 and EP 0436061, already of record, May 12, 2009.
Fordtran et al.,Gastrointestinal Disease, Pathophysiology/ Diagnosis/Management, vol. 2, Ed: J.S., Chapter 49, p. 1051, col. 2, line 46, (1993).
Kolts et al., A Comparison of the Effectiveness and Patient Tolerance of Oral Sodium Phosphate, Castor Oil, and Standard Electrolyte Lavage for Colonscopy or Sigmoidoscopy Preparation,The American Journal of Gastroenterology, 88(8): 1218-1223 (1993).
Notice of Litigation: Defendant Novel Laboratories Answer to first amended Complaint and Counterclaims, Civil Action No. 08-02311(FLW)(TJB), US District of New Jersey (litigation commenced May 14, 2008).
Rote-Liste, XP002268214 (See entry 35-075 under Klean-Prep), as cited in the ISR (English translation provided), Mar. 19, 2004.
Notice of Litigation: Defendant Novel Laboratories invalidity contentions pursuant to L. Pat. R. 3.3, Civil Action No. 08-02311 (FLW)(TJB), US District of New Jersey (litigation commenced May 14, 2008).
Gruber et al., Palatability of Colonic Lavage Solution Is Improved by the Addition of Artificially Sweetened Flavored Drink Mixes,Gastroenterology Nursing, 14(3) (1991).
Printout from Kraftfoods' webpage (1 page), Sep. 2009.
Martindale,The Complete Drug Reference, (Kathleen Parfitt ed., Pharmaceutical Press, 32nd ed. 1999).
Minegishi et al., Evaluation of Pretreatment Methods in Colonoscopy at Difference Osmotic Pressures,Journal of New Remedies&Clinics, 44(3) (1995)(English translation attached).
Physicians' Desk Reference 1990 (Medical Economics Data, 44th ed. 1990).
Adorsky et al.,Am. J. Gastroenterol., 85(3): 261-265 (1990).
Clarkston et al.,Gastrointestinal Endoscopy, 43(1): 42-49 (1996).
Davis et al.,Gastroenterology, 78(5): 991-995 (1980).
Fordtran et al.,Gastroenterology, 98: 11-16 (1990).
Hammer et al.,J. Clin. Invest., 84: 1056-1062 (1989).
Ingebo et al.,Am. J. Dis. Child, 142: 340-342 (1988).
Merolli,Food Product Design, (1997).
Poon et al.,Endoscopy, 23(7): 560-563 (2002).
Puxty et al.,Age and Aging, 15: 182-184 (1986).
Regev et al.,Am. J. Gastroenterol., 93(9): 1478-1482 (1998).
Remington's Pharmaceutical Sciences(Sixteenth Edition), Structure Activity Relationship and Drug Design, Mack Publishing, pp. 420-425 (1980).
Stedman's Medical Dictionary(Twenty-Second Edition), Magnesium Sulfate, Williams and Wilkins Company, p. 737 (1972).
The Merck Index(Twelfth Edition), Sodium Ascorbate, Monograph 8723, Merck & Co., Inc. p. 1471, 1996.
Thomas et al.,Gastroenterology, 82: 435-437 (1982).
Tolia,J. Pediatr. Gastrenterol. Nutr., 7(2): 299-301 (1988).
notice of litigation: Defendant Novel Laboratories, Inc. Answer and Counterclaims, Civil Action No. 3:08-cv-02311-FLW-TJB, US District Court, District of New Jersey (litigation commenced May 14, 2008).
Paragraph IV Notice served on Norgine Europe B.V. by Novel Laboratories, Inc. in connection with abbreviated new drug application of Novel—document redacted to mask proprietary formulation and submitted under seal pursuant to MPEP § 724.02 to protect confidentiality claimed by Novel—to be unsealed only by the Examiner or other authorized Patent Office personnel, Jun. 20, 2008.

Affiliated with

Also associated with

Rating

Colon cleansing compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Colon cleansing compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Colon cleansing compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4177848